CDTX Earnings

CDTX reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of against an estimate of 25.75M, resulting in a 0% surprise. The EPS was -1.43, surpassing the expected -1.19 by -20.17%. The stock experienced a 5.83% price change on the earnings day and a 8.6% change over the next five days, reflecting market reactions to the results.

Following CDTX's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by 5.83% on the day of the release. Over the subsequent five days, it saw a 8.6% change. Historically, CDTX's stock price tends to shift by an average of 11.42% in the 10 days leading up to earnings and 16.8% in the 10 days following, providing insight into potential market.

For , analysts estimate CDTX's annual revenue to reach , while the EPS is projected at -1.51. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised upward by 0.68% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CDTX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised upward by 0.68%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CDTX's stock price typically moves by 11.42% in the 10 days before its earnings and 16.8% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -1.51 and revenue of .

The earnings call summary and Q&A highlight significant positive developments, including a substantial BARDA award, strong financial backing, and progress in manufacturing scale-up. Although management withheld some efficacy data, the overall sentiment is optimistic with potential market expansion and strong interest in CD388. The strategic plan and funding provide a solid foundation for future growth, outweighing concerns over interim analysis data. Given these factors, a positive stock price reaction is anticipated.